No

Antiretroviral Agent, Reverse Transcriptase Inhibitor (Non-Nucleoside); Antiretroviral Agent, Reverse Transcriptase Inhibitor (Nucleoside)

Treatment of HIV infection when therapy is warranted based on clinical and/or immunological evidence of disease progression. Combivir® given twice daily, provides an alternative regimen to lamivudine 150 mg twice daily plus zidovudine 600 mg/day in divided doses; this drug form reduces capsule/tablet intake for these two drugs to 2 per day instead of up to 8.

C

See individual agents

See individual agents

The combination of zidovudine and lamivudine are believed to act synergistically to inhibit reverse transcriptase via DNA chain termination after incorporation of the nucleoside analogue as well as to delay the emergence of mutations conferring resistance

Half-life: Zidovudine: 0.5-3 hours; lamivudine: 5-7 hours

Children >12 years and Adults: Oral: One tablet twice daily

Dizziness, insomnia, sedation are common; may cause depression. May rarely cause confusion or mania

Leukopenia and granulocytopenia are common; caution with clozapine and carbamazepine. Increased toxicity may result if used concurrently with drugs that inhibit glucuronidation or excretion (lorazepam). Valproic acid increased zidovudine's AUC by 80% and decreased clearance by 38%.

No information available to require special precautions

No effects or complications reported

Combivir® is not a cure for HIV and you may continue to experience HIV-associated illness. Major toxicities are neutropenia and/or anemia; have blood counts checked regularly while on therapy.

Tablet: Zidovudine 300 mg and lamivudine 150 mg